Grace Therapeutics Announces Submission Of New Drug Application To US FDA For Gtx-104
June 25 (Reuters) - Grace Therapeutics, Inc GRCE.O:
GRACE THERAPEUTICS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR GTX-104
GRACE THERAPEUTICS- NDA SUBMISSION INCLUDES POSITIVE DATA FROM PHASE 3 STRIVE-ON TRIAL
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
ORCL Stock: Why Oracle May Be the Beaten-Down Tech Giant Ready for a Comeback

Nvidia Makes First Bet on Legal AI, Invests $50 Million in Legora

Palantir Q1 2026 Earnings Preview — Is PLTR a Buy at $144?

POET Technologies Stock Could Still Surge in 2026, but the Bar for a Breakout Is Higher Now

From Underdog to AI Infrastructure Leader: Is AMD Poised for Growth in 2026?

Tradingkey







